Intervention

Acamprosate

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 5 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5

Recruiting0

Common conditions12

Lead sponsors shown5

Clinical trials

5 shown

Vortioxetine for Treatment of Depressive Mood and Alcohol UseNCT04498897 · 2019-01-25

UNKNOWN

Pharmacovigilance in Gerontopsychiatric PatientsNCT02374567 · 2015-01-01

TERMINATED

Biomarker Study of Acamprosate in SchizophreniaNCT00688324 · 2008-06-01

COMPLETED

Treatment With Acamprosate in Patients With Schizophrenia and Comorbid AlcoholismNCT00463346 · 2006-09-01

COMPLETED

Acamprosate in Alcoholics With Comorbid Anxiety or DepressionNCT00330174 · 2006-04-01

COMPLETED

Common conditions

Schizophrenia3 Alcohol Dependence2 Alcoholism1 Anxiety Disorders1 Dementia1 Depression1 Depressive Disorder, Major1 Generalized Anxiety Disorder1 Major Depression1 Psychosomatic Disorders1 Schizoaffective Disorder1 Social Anxiety Disorder1

Leading sponsors

Hannover Medical School1 Hanyang University Seoul Hospital1 Medical University of South Carolina1 University of Maryland, Baltimore1 Yale University1

Trial status mix

COMPLETED3

TERMINATED1

UNKNOWN1

Phase mix

PHASE32

PHASE42

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.